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Abstract One of the significant oncogen proteins is 
Tropomyosin Related Kinase B (Trk B) which its ligand is Brain 
Derived Neurotrophic Factor (BDNF). Over-expression of Trk B 
was observed in thyroid, ovarian and prostate cancer and multiple 
myeloma. BDNF bind to Trk B receptor which leads to activation of 
angiogenesis and proliferation pathway in tumor cell line. The aim 
of this study was to design novel peptides as inhibitors of Trk B 
receptor. Firstly, peptide library was generated; bioinformatics 
software for opting peptides with lowest energy, then the designed 
peptides were treated on OV-CAR-3 Cell line. MTT Assay was 
carried out to investigate the cytotoxicity and apoptosis in 
OV-CAR-3 Cell line resulting from designed peptides. Our findings 
indicated that  peptide II with 350 nM is more effective OV-CAR-3
than other designed peptides, it could inhibit signaling pathway. 
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I. INTRODUCTION
ANCER is the second cause of death in the world wild 
and Millions of people are suffering from cancer [1].
There are many ways for cancer treatment including surgery, 
radiation therapy, chemotherapy, targeted therapies like 
monoclonal antibody and therapeutic peptides [2]. The 
peptide has many advantages than others including smaller 
size, high structural compatibility with target proteins and 
fewer drug-drug interaction complications [3], [4]. Many 
proteins including RAS, WNT, MYC, ERK and TRK; So 
TRK have been identified as a drug target in cancer; Trk B 
receptor  acts as an oncogen agent and its binding to BDNF 
ligand  activates the signaling angiogenesis of tumor 
proliferation [5]. After binding BDNF to cyctoplasmi Trk B 
receptor cause autophosphorization Y484 ,Y785 actives 
some signaling including phosphatidyl inositol 3-kinase 
(PI3K) active survival and growth , MAPK/ERK and 
RAS/MAPK differentiation and growth also AKT cause 
decreasing of pro apoptotic proteins [6],[7]. Trk B inhibition 
is potential target for treatment of some cancers [5, 8]
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because over expression and mutation in Trk B are 
determined in ovarian, bladder, neuroblastoma, prostate, 
multiple myeloma [9], [10]. In this study we set up a 
computational method for designing novel stable peptides for 
inhibition of Trk B as cell membrane receptor of BDNF.  
II. MATERIAL AND METHODS
We designed a pepetide to disrupt its binding to BDNF and 
blocking the activation pathways of angiogenesis .At the first 
step, a peptide library generated. Then generated peptides 
sorted based on energy score in R package. Three 
dimensional Structures of the selective peptides with the 
lowest energy predicted by using molecular dynamic method 
in Hyperchem 7 software. 
III. RESULTS
Storing designed peptides and 3D- structure of them are 
shown in figure 1 and 2. MTT assay was done in 200 and 350
nM , IC50 of 200 and  350 nM was shown in figure3. For 
OV-CAR-3 after the treatment of designed inhibitory peptide 
I at concentrations 200, 350, nM at 24h were  340.92 nM 
while for designed  peptide II at concentration 200, 350 nM 
at 24h were 199.52, our result shown peptide II is more 
effective than peptide I ( Figures I and II, Table I).
Fig.1 the five peptides with lowest energy is above of dot, are sorted 
by R package 
 Fig. 2 three dimensional of designed peptides 
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